Premedication with a combination of histamine H 1 receptor (H 1 R) and H 2 receptor (H 2 R) antagonists has been suggested as a prophylactic principle, for instance, in anaesthesia and surgery. Aiming at pharmacological hybrids combining H 1 R and H 2 R antagonistic activity, a series of cyanoguanidines 14-35 was synthesized by linking mepyramine-type H 1 R antagonist substructures with roxatidine-, tiotidine-, or ranitidine-type H 2 R antagonist moieties. N-desmethylmepyramine was connected via a poly-methylene spacer to a cyanoguanidine group as the "urea equivalent" of the H 2 R antagonist moiety. The title compounds were screened for histamine antagonistic activity at the isolated ileum (H 1 R) and the isolated spontaneously beating right atrium (H 2 R) of the guinea pig. The results indicate that, depending on the nature of the H 2 R antagonist partial structure, the highest H 1 R antagonist potency resided in roxatidine-type compounds with spacers of six methylene groups in length (compound 21), and tiotidine-type compounds irrespective of the alkyl chain length (compounds 28, 32, 33), N-cyano-N'-[2-[[(2-guanidino-4-thiazolyl) (25, pK B values: 8.05 (H 1 R, ileum) and 7.73 (H 2 R, atrium) and the homologue with the mepyramine moiety connected by a six-membered chain to the tiotidine-like partial structure (compound 32, pK B values: 8.61 (H 1 R) and 6.61 (H 2 R) were among the most potent hybrid compounds. With respect to the development of a potential pharmacotherapeutic agent, structural optimization seems possible through selection of other H 1 R and H 2 R pharmacophoric moieties with mutually affinity-enhancing properties.